{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:26Z","timestamp":1786991966947,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jdcr.2019.02.008","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T17:57:54Z","timestamp":1554487074000},"page":"362-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pembrolizumab-induced bullous pemphigoid"],"prefix":"10.1016","volume":"5","author":[{"given":"Christina W.","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana K.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Aphale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2019.02.008_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jdermsci.2013.12.001","article-title":"Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII","volume":"73","author":"Nishie","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jdcr.2019.02.008_bib2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0190-9622(93)70262-R","article-title":"Antigen identification in drug-induced bullous pemphigoid","volume":"29","author":"Smith","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2019.02.008_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2019.02.008_bib4","first-page":"1","article-title":"Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitory anti-CTLA-4 and anti-PD-1","volume":"5","author":"Kong Yi-Chi","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdcr.2019.02.008_bib5","first-page":"267","article-title":"Immune checkpoint inhibitors: therapeutic advances in melanoma","volume":"3","author":"Marquez-Rodas","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jdcr.2019.02.008_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events of anti-programmed cell death 1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2019.02.008_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2019.02.008_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000489661","article-title":"Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports","volume":"10","author":"Thomsen","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jdcr.2019.02.008_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jdcr.2019.02.008_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2018.05.873","article-title":"Pembrolizumab-induced bullous pemphigoid","volume":"79","author":"Kartha","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512619300608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512619300608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:19:43Z","timestamp":1762474783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512619300608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2352512619300608"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2019.02.008","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2019.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}